This category page covers biotechnology and pharmaceutical companies developing complement system inhibitors for Alzheimer's disease. The complement system — a key component of innate immunity — is increasingly recognized as a major driver of synapse loss, neuroinflammation, and disease progression in AD. Complement activation (particularly the classical pathway via C1q) promotes microglial pruning of synapses, and C3 activation drives chronic neuroinflammation. Several companies are now targeting specific complement proteins with monoclonal antibodies, small molecules, and other inhibitors[@complement2024].
The main complement targets in AD include:
Mechanism: C1q inhibitor (humanized monoclonal antibody)
Clinical Stage: Phase 3 (GUARDIAN-AD trial for early AD)
Background: Annexon's ANX005 is the most advanced complement inhibitor in AD. C1q is the initiating molecule of the classical complement pathway and drives synapse loss through microglia-mediated pruning. By blocking C1q, ANX005 prevents complement activation at the synapse, potentially protecting against cognitive decline[@annexon2024].
Key Data:
Pipeline:
Company: Annexon Biosciences (NASDAQ: ANXN)
Mechanism: C3 inhibitor (gene therapy approach)
Clinical Stage: Preclinical
Background: Alcyone is developing C3 inhibitors using a novel gene therapy approach to achieve sustained complement inhibition in the CNS. Unlike antibody approaches, gene therapy may provide durable complement blockade without repeated dosing[@alcyone2024].
Mechanism: C3 inhibitor (small molecule)
Clinical Stage: Preclinical / research
Background: Travere has expanded its complement platform beyond rare kidney disease into neurodegenerative indications. Their C3 inhibitors are designed to cross the BBB and achieve CNS penetration[@travere2024].
Multiple academic groups and early-stage companies are developing complement inhibitors:
| Company | Target | Approach | Stage |
|---|---|---|---|
| Roche | C5 | Monoclonal antibody | Preclinical |
| AbbVie | C3 | Small molecule | Discovery |
| Academic (UCL) | C1q | Peptide inhibitors | Research |
| Academic (Stanford) | Factor D | Small molecules | Research |
| Target | Drug | Company | Stage | Mechanism |
|---|---|---|---|---|
| C1q | ANX005 | Annexon | Phase 3 | Blocks classical pathway initiation |
| C3 | Various | Multiple | Preclinical | Blocks all downstream complement effects |
| C5 | Various | Multiple | Discovery | Blocks terminal membrane attack complex |
| Trial ID | Drug | Phase | Population | Status |
|---|---|---|---|---|
| NCT05806954 | ANX005 | Phase 3 | Early AD (MCIs) | Recruiting |
| NCT05216038 | ANX005 | Phase 2 | AD (completed) | Data published |
| — | C3 inhibitor | Preclinical | AD | Research |
C1q, the initiating molecule of the classical complement pathway, binds directly to Aβ oligomers and localizes to synapses in AD brains. This triggers complement activation leading to C3b deposition on synapses, which marks them for elimination by microglia. Studies in mouse models show that blocking C1q or C3 prevents synapse loss and preserves cognitive function even in the presence of amyloid pathology[@complement2024].
Resting microglia continuously survey synapses, eliminating weak or unnecessary connections through complement-mediated pruning. In AD, this process becomes pathological — Aβ oligomers trigger excessive C1q deposition, causing microglia to eliminate healthy synapses. This represents a fundamental reconfiguration of the pruning mechanism from a developmental cleanup process to a driver of neurodegeneration.
Complement activation generates inflammatory mediators (C3a, C5a) that attract immune cells, activate glia, and promote a chronic inflammatory state. This creates a feedforward loop where inflammation drives more complement activation, which drives more inflammation and synaptic damage.
| Company | Target | Stage | Differentiation |
|---|---|---|---|
| Annexon | C1q | Phase 3 | First-in-class; blocks upstream |
| Roche | C5 | Preclinical | BBB-penetrant antibody |
| AbbVie | C3 | Discovery | Small molecule approach |
| Alcyone | C3 | Preclinical | Gene therapy for sustained inhibition |